4-chloromethyl-2-(4-tert-butyl phenyl)-thiazole | 620115-82-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloromethyl-2-(4-tert-butyl phenyl)-thiazole
• 英文别名: 2-(4-tert-butyl-phenyl)-4-chloromethyl-thiazole；4-chloromethyl-2-(4-tert-butyl phenyl) thiazole；4-chloromethyl-2-(4-t-butyl phenyl) thiazole；4-chloromethyl-2-(4-t-butyl phenyl)-thiazole；4-Chloromethyl-2-(4-tert-butyl phenyl)thiazole；2-(4-tert-butylphenyl)-4-(chloromethyl)-1,3-thiazole
• CAS: 620115-82-4
• 化学式: C₁₄H₁₆ClNS
• mdl: MFCD11179571
• 分子量: 265.807
• InChiKey: DFIOCDQLQBUSTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloromethyl-2-(4-tert-butyl phenyl)-thiazole 生成 N-{5-[2-(4-tert-Butyl-phenyl)-thiazol-4-ylmethoxy]-naphthalen-2-yl}-C,C,C-trifluoro-methanesulfonamide
  参考文献：
  名称：

  Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus

  摘要：

  这项发明提供了具有结构的I式化合物，其结构如下： 其中R 1 ，R 4 ，A和Z如规范中定义，或其药学上可接受的盐，可用于治疗由胰岛素抵抗或高血糖介导的代谢紊乱。

  公开号：

  US20030216442A1
• 作为产物：
  描述：

  [2-(4-Tert-butylphenyl)-1,3-thiazol-4-yl]methanol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-chloromethyl-2-(4-tert-butyl phenyl)-thiazole
  参考文献：
  名称：

  Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

  摘要：

  A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi-and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.072

文献信息

• [EN] NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS<br/>[FR] NOUVEAUX COMPOSES 2-ARYLTHIAZOLE UTILISES COMME AGONISTES DES RECEPTEURS PPARALPHA ET PPARGAMMA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004020420A1

  公开（公告）日：2004-03-11

  The present invention relates to compounds of formula (I) wherein Rl to R10, X, Y and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

  本发明涉及式(I)的化合物，其中R1至R10、X、Y和n如描述和权利要求中所定义，并且其药学上可接受的盐和酯。这些化合物对于治疗疾病如糖尿病是有用的。
• Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus
  申请人：Wyeth

  公开号：US20030203941A1

  公开（公告）日：2003-10-30

  This invention provides compounds of formula I, having the structure 1 wherein R 1 , R 2 , R 3 , R 4 , A, and B are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.

  该发明提供了公式I的化合物，具有结构1，其中R1、R2、R3、R4、A和B如规范中定义，或其药用盐，可用于治疗由胰岛素抵抗或高血糖介导的代谢紊乱。
• Thiazole derivatives
  申请人：——

  公开号：US20040110807A1

  公开（公告）日：2004-06-10

  The present invention provides compounds of formula (I) 1 wherein R 1 to R 10 , X, Y and n are indicated in the specification, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of non-insulin dependent diabetes mellitus.

  本发明提供了式(I)1的化合物，其中R1至R10、X、Y和n在规范中指定，并且其药学上可接受的盐和酯。该化合物可用于治疗非胰岛素依赖型糖尿病。
• Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM)
  申请人：Sabatucci Joseph P.

  公开号：US06930131B2

  公开（公告）日：2005-08-16

  This invention provides compounds of formula I, having the structure wherein R 1 , R 2 , R 3 , R 4 , A, and B are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.

  本发明提供了式I的化合物，其结构如下： 其中R1、R2、R3、R4、A和B如规范中所定义，或其药学上可接受的盐，用于治疗由胰岛素抵抗或高血糖介导的代谢性疾病。
• NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1537091A1

  公开（公告）日：2005-06-08